EP3407890B1 - Préparation pharmaceutique et son utilisation pour le traitement de la laryngite virale - Google Patents

Préparation pharmaceutique et son utilisation pour le traitement de la laryngite virale Download PDF

Info

Publication number
EP3407890B1
EP3407890B1 EP17700818.2A EP17700818A EP3407890B1 EP 3407890 B1 EP3407890 B1 EP 3407890B1 EP 17700818 A EP17700818 A EP 17700818A EP 3407890 B1 EP3407890 B1 EP 3407890B1
Authority
EP
European Patent Office
Prior art keywords
preparation
use according
pharmaceutical preparation
combinations
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP17700818.2A
Other languages
German (de)
English (en)
Other versions
EP3407890A1 (fr
EP3407890C0 (fr
Inventor
Peter Sommer
Nicola VAUBEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SOMMER, PETER
Vaubel Nicola
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP3407890A1 publication Critical patent/EP3407890A1/fr
Application granted granted Critical
Publication of EP3407890B1 publication Critical patent/EP3407890B1/fr
Publication of EP3407890C0 publication Critical patent/EP3407890C0/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Definitions

  • the invention relates to a pharmaceutical preparation for topical-oral application to mucous membranes in the larynx and/or pharynx and its use for the symptomatic therapy of viral laryngitis.
  • the pharmaceutical preparation can be used successfully to prevent the occurrence of symptoms, to alleviate symptoms and for the causal therapy of inflammatory, virus-induced laryngitis.
  • Respiratory diseases are diseases that primarily affect the respiratory system, particularly the mucous membranes of the respiratory system. Respiratory diseases are classified according to ICD 10 ("International Classification of Diseases"). Particularly inflammatory infections of the upper respiratory tract (ICD 10, J00-J06), for example pharyngitis, tonsillitis, laryngitis, can currently only be treated symptomatically. This is especially true for viral, inflammatory diseases of the upper respiratory tract.
  • the EP 2 110 116 A1 describes an aqueous antiseptic preparation for the treatment of the mouth and throat which, in addition to chlorhexidine, contains herbal active ingredients and an alkali metal and/or alkaline earth metal fluoride. This preparation is used to disinfect and reduce inflammation in the mouth and throat.
  • the EP 1 595 537 A1 describes an antimicrobial preparation for treating the oral cavity containing a compound composed of chlorhexidine and triclosan with a zinc salt. This composition is intended to counteract the discoloration of teeth by chlorhexidine.
  • the WO 2009/106963 A2 describes a dental preparation for the prevention and treatment of stomatitis, ulcers of the oral mucosa and damage to the mucous membrane.
  • a liquid myrrh extract and a soluble zinc salt are used in addition to optional compounds such as chlorhexidine digluconate.
  • the EP 2 614 812 A1 describes a mouthwash containing chlorhexidine, an alkali or alkaline earth metal metabisulfite salt, ascorbic acid, and hyaluronic acid in salt or complex form.
  • the WO 92/18133 A1 describes the treatment of inflammatory diseases of the mouth using a corticoid, an antihistamine, a local anesthetic and an antibiotically active fungicide in an aqueous medium as a mouthwash.
  • the US 2010/0190735 A1 describes a pharmaceutical preparation containing cortisone for oral hygiene, in particular mouthwashes for the treatment and prevention of mucositis and stomatitis.
  • the EP 0 579 435 A1 describes the use of certain polymers in the preparation of cyclodextrin-drug complexes to increase the solubility and stability of cyclodextrin derivatives of drugs complexed therewith.
  • the WO 2014/145602 A1 describes a composition comprising a polyphenol and an orally acceptable carrier, wherein the polyphenol is in the form of an alkali metal salt or a concentrate.
  • Laryngitis, BMJ 2014;349:g5827 provides an overview of laryngitis and suggests voice hygiene and erythromycin for therapy.
  • Laryngitis is the inflammation of the larynx mucosa, which leads to hoarseness and even voicelessness and is very often accompanied by a dry, agonizing cough. Other symptoms include a severe sore throat or fever. Laryngitis can occur in both acute and chronic forms. The acute form is divided into inflammation of the various floors of the larynx, supraglottis, glottis, subglottis. Acute laryngitis is mainly caused by viral infections, such as rhinovirus, influenza virus, parainfluenza virus, adenovirus, coxsackie virus, coronavirus and respiratory syncytial virus, of the upper respiratory tract or by severe voice strain.
  • viral infections such as rhinovirus, influenza virus, parainfluenza virus, adenovirus, coxsackie virus, coronavirus and respiratory syncytial virus, of the upper respiratory tract or by severe voice strain.
  • a disadvantage of the previously known treatment methods is that only an incomplete alleviation of the symptoms and no fight against the viral cause is possible, which often leads to a subsequent bacterial secondary infection. Furthermore, several preparations must be used simultaneously and regularly throughout the day, which can lead to reduced patient compliance and thus endanger the success of the therapy. Insufficient therapy can develop from an initially acute to a manifest, chronic inflammation of the upper respiratory tract with associated secondary bacterial infection. There is currently no combination product on the market that relieves the symptoms and treats the underlying viral disease.
  • one object of the invention is to provide an alternative antiviral pharmaceutical preparation for the symptomatic therapy of virally caused, inflammatory diseases of the upper respiratory tract.
  • viral laryngitis which belongs to the viral, inflammatory diseases of the upper respiratory tract according to ICD 10, preferably viral, inflammatory diseases of the oral /pharynx (J00-J06).
  • the individual components can have a variety of effects when taken individually, the components used individually are only able to bring about relief of symptoms.
  • the pharmaceutical preparation according to the invention not only alleviates the symptoms of viral, inflammatory diseases of the upper respiratory tract, but also develops an antiviral effect. In this way, the frequently occurring bacterial secondary infection can also be treated preventively.
  • the pharmaceutical preparation according to the invention has proven to be particularly effective for the therapy of viral laryngitis.
  • laryngitis is mentioned here or in the following, all forms of viral laryngitis are meant.
  • the pharmaceutical preparation according to the invention By using the pharmaceutical preparation according to the invention, viral, inflammatory diseases of the upper respiratory tract can be successfully treated, the risk of a bacterial secondary infection can be reduced or even its development can be completely prevented.
  • the pharmaceutical preparation according to the invention can therefore be used preventively, in the acute or chronic stage of the disease.
  • the pharmaceutical preparation according to the invention which contains at least components a) to e), is a combination preparation and not, as previously, several different drugs in different application forms have to be used, which in turn have to be taken at different times. This not only significantly reduces the number of medications to be taken, but also increases patient compliance and the associated success of the therapy. This may also help reduce the risk of developing chronic inflammatory airway disease and the cost of the daily dose.
  • the anti-inflammatory and anti-viral effect is probably developed through the synergistic effect of components a) to e). It has been shown that the pharmaceutical preparation according to the invention can also prevent wound infections, curb or eliminate inflammatory processes on the mucous membranes and have an antiviral effect.
  • antiviral when “antiviral” is mentioned here or elsewhere, it means that the viral load is reduced, the virus is inactivated, destroyed, viral growth, reproduction and/or spread is inhibited.
  • a further advantage is that the pharmaceutical preparation according to the invention can be formulated galenically in such a way that it is available in an application form that is pharmaceutically acceptable and easy to use for the patient.
  • the pharmaceutical preparation according to the invention contains a corticosteroid as component a).
  • the active ingredient class of corticoids, the pharmacological effect, the selection of the corticoid to be used pharmaceutically, the areas of application or indications and dosages are generally known to the person skilled in the art (cf. Drug Effects, Pharmacology - Clinical Pharmacology - Toxicology, Ernst Mutschler, Gerd Geisslinger, Heyo K. Kroemer, Sabine Menzel, Peter Ruth, 2001, p. 721ff ).
  • the pharmaceutical preparation according to the invention contains component a) in an amount of 0.01 to 0.7% by weight, preferably 0.045 to 0.075% by weight and particularly preferably 0.05 to 0.065% by weight, based on the total weight of the pharmaceutical preparation.
  • salt or salt form of the component is suitable for use in a pharmaceutical formulation and/or is harmless to humans or animals.
  • pharmaceutically tolerable salts are known in principle to the person skilled in the art.
  • the pharmaceutical preparation according to the invention contains a metal as component b).
  • the pharmaceutical preparation according to the invention contains component b) in an amount of 0.01 to 5% by weight, preferably 0.03 to 4% by weight and particularly preferably 0.02 to 3.5% by weight, based on the total weight of the pharmaceutical preparation.
  • the metal can be selected from Mn, Ag, Zn, Sn, Fe, Cu, Al, Ti and combinations thereof. However, other metals which can develop an antiviral effect are also conceivable.
  • the metal may be present as a pharmaceutically acceptable salt, pharmaceutically acceptable form and/or preparations thereof.
  • the metal may be in the form of a powder, solution, colloidal solution or suspension.
  • the metal in a metal-protein compound or a metal-protein complex.
  • the metal-protein compound or metal-protein complex can be present as a salt, in a compound or a complex with one of components a), c), d), e) and/or another additive.
  • the metal is present in a silver-protein compound.
  • the metal is present as silver protein, in particular silver protein acetyltannate.
  • the pharmaceutical preparation according to the invention contains an astringent as component c).
  • Adstingentia are well known to those skilled in the art ( Pschyrembel clinical dictionary, Willibald Pschyrembel, Otto Dornblüth, Christoph Zink, p. 23, 1986 ).
  • the amount of component c) contained in the pharmaceutical preparation according to the invention is 0.01 to 5% by weight, preferably from 0.03 to 4% by weight and particularly preferably from 0.02 to 3.5% by weight, based on the total weight of the pharmaceutical preparation.
  • the astringent can be selected from catechin tanning agents, polymeric proanthocyanidins, oligomeric proanthocyanidins, oligomers or polymers of catechins, catechin, epicatechin, flavonoids, hydrolyzable tanning agents, gallotannins, esters of gallic acid or derivatives thereof, tannins, caffeic acid and phloroglucin derivatives, labiate tanning agents, rosmarinic acid or derivatives thereof, alum, alumina and combinations thereof.
  • the pharmaceutical preparation according to the invention comprises a disinfectant as component d).
  • Disinfectants for pharmaceutical purposes are well known to those skilled in the art ( Pschyrembel clinical dictionary, Willibald Pschyrembel, Otto Dornblüth, Christoph Zink, p. 340, 1986 ).
  • the preparation according to the invention contains component d) in an amount of 0.005 to 0.03% by weight, preferably 0.005 to 0.02% by weight and particularly preferably 0.008 to 0.01% by weight, based on the Total weight of the pharmaceutical preparation.
  • the disinfectant can be selected from chlorhexidine, hexetidine, ethanol, propanol, dichlorobenzyl alcohol, amylmetacresol, menthol, levomenthol, dequalinium chloride, iodine, povidone iodine, gentian violet, and combinations thereof.
  • the preparation according to the invention contains hyaluronic acid as component e).
  • the structure, occurrence, effect and pharmaceutically applicable forms of hyaluronic acid are generally known to the person skilled in the art ( Pschyrembel clinical dictionary, Willibald Pschyrembel, Otto Dornblüth, Christoph Zink, p. 718, 1986 ).
  • the amount of component e) contained in the pharmaceutical preparation according to the invention is 0.01 to 0.06% by weight, preferably from 0.02 to 0.04% by weight and particularly preferably from 0.025 to 0.035% by weight, based on the total weight of the pharmaceutical preparation.
  • the hyaluronic acid can be present as a pharmaceutically acceptable salt, in a pharmaceutically acceptable form and/or preparations thereof. In one embodiment of the invention, the hyaluronic acid is present as the sodium salt of hyaluronic acid (sodium hyaluronate).
  • the pharmaceutical preparation according to the invention is supplemented with at least one or more pharmaceutically tolerable solvent(s) to an extent of 100% by weight, based on the total weight of the pharmaceutical preparation.
  • the solvent can be water and/or ethanol.
  • the solvent is water, in particular purified water (aqua purificata).
  • the pharmaceutical preparation contains purified water and ethanol.
  • a powder-based spray is also conceivable.
  • the pharmaceutical preparation can have at least one further component f) and/or g).
  • at least one essential oil in an amount of 0.01 to 0.4% by weight, preferably 0.1 to 0.35% by weight and particularly preferably from 0.2 to 0.3% by weight, based on the total weight of the pharmaceutical preparation.
  • the essential oil may be derived from or obtainable from orange, chamomile, yarrow, sage and/or peppermint.
  • peppermint oil (oleum menthae piperitae) is used as the essential oil in the pharmaceutical preparation.
  • the pharmaceutical preparation contains ethanol (90%) as an additional component g) in an amount of 10.0 to 40.0% by weight, preferably 20 to 30% by weight and particularly preferably 23 to 26% % by weight based on the total weight of the pharmaceutical preparation.
  • the pharmaceutical preparation can optionally contain at least one further additive in addition to components a) to e).
  • the additive can be used to adjust the pH value, viscosity, improve the dissolving properties of the individual components, stability, shelf life, taste or appearance.
  • the additive may also be another substance that aids in symptom relief and/or antiviral activity. Such additives are known in principle to those skilled in the art.
  • Additives according to the invention can be selected from pharmaceutical excipients, pharmaceutical excipients, sugar substitutes, sugar substitutes, acidifiers, solubilizers, thickeners, fillers, dyes, preservatives, aromas, flavorings, local anesthetics, provitamins, in particular dexpanthenol, vitamins and combinations thereof.
  • the pH of the pharmaceutical preparation is in a physiologically tolerable pH range.
  • the pharmaceutical preparation exhibits a pH of 3.5 to 7.5.
  • the pharmaceutical preparation contains at least one additional component f), g) and/or a further additive.
  • the pharmaceutical preparation is present in a suitable galenic formulation. If “suitable galenic formulation” is mentioned here, then this means that the pharmaceutical preparation is in a form which is suitable for use in the upper respiratory tract.
  • the pharmaceutical preparation can be applied directly into the respiratory passage or onto the mucous membranes of the pharynx and/or mouth.
  • Galenic formulations within the meaning of the invention can be solutions, colloidal solutions, suspensions, drops, sprays, in particular pump sprays, pressurized sprays, atomizers, air inhalation devices and/or known suitable forms of administration.
  • the pharmaceutical preparation contains pharmaceutical and/or galenic excipients which contribute to the production of a suitable galenic formulation.
  • the pharmaceutical preparation is in the form of a spray.
  • Such sprays can be used particularly easily in the pharynx. They are suitable for applying the pharmaceutical preparation to hard-to-reach places in the mouth/throat area and/or larynx area.
  • the preparation according to the invention can also be brushed onto the areas to be treated.
  • dexamethasone acetate is dissolved in ethanol.
  • Hyaluronic acid sodium salt and chlorhexidine digluconate are dissolved in a portion of the purified water.
  • Silver protein acetyltannate is colloidally dissolved in the mixture thus obtained.
  • the dexamethasone acetate/ethanol solution is added and peppermint oil is dripped into the resulting mixture. It is then made up to 100% by weight with purified water.
  • the resulting pharmaceutical preparation is filled into a spray bottle with an atomizer.
  • Example 1 The preparation produced according to Example 1 was applied as a spray solution over a period of 4 to 9 days. After two days of application, there was a subjectively significant improvement in hoarseness and sore throat in all patients. One patient's dry cough only improved after 7 days.
  • Exclusion criteria were visible purulent deposits on the vocal cords or in the area of the upper respiratory tract, a known allergy to a component of the solution, or known diabetes mellitus.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Claims (13)

  1. Préparation pharmaceutique destinée à être appliquée par voie topique/orale sur des muqueuses dans le larynx et/ou le pharynx, caractérisée en ce qu'elle comprend au moins les composants suivants
    a) 0,01 à 0,7 % en poids d'un corticoïde,
    b) 0,01 à 5 % en poids d'un composé métallique,
    c) 0,01 à 5 % en poids d'un astringent,
    d) 0,005 à 0,03 % en poids d'un désinfectant et
    e) 0,01 à 0,06 % en poids d'acide hyaluronique/sel d'acide hyaluronique,
    la préparation étant complétée à 100 % en poids par un solvant pharmaceutiquement acceptable, laquelle préparation étant destinée à être utilisée dans le traitement symptomatique d'une laryngite virale.
  2. Préparation destinée à être utilisée selon la revendication 1,
    caractérisée en ce qu'elle comprend en outre, comme composant
    f) 0, 01 à 0,4 % en poids d'une huile essentielle.
  3. Préparation destinée à être utilisée selon la revendication 1 ou 2, caractérisée en ce qu'elle comprend en outre, comme composant
    g) 10,0 à 40,0 % en poids d'éthanol.
  4. Préparation destinée à être utilisée selon la revendication 1 ou 2, caractérisée en ce que le corticoïde est choisi parmi la dexaméthasone, hydrocortisone, prednisolone, clobétasone, flumétasone, fluocortine, flupérolone, fluorométholone, fluprednidène, désonide, triamcinolone, alclométasone, butéprate d'hydrocortisone, clocortolone, bétamethasone, fluclorolone, désoximétasone, acétonide de fluocinolone, fluocortolone, diflucortolone, fludroxycortide, fluocinonide, budésonide, diflorasone, amcinonide, halométasone, acéponate de méthylprednisolone, béclométasone, acéponate d'hydrocortisone, fluticasone, prednicarbate, difluprednate, ulobétasol, clobétasol, halcinonide, leurs sels pharmaceutiquement acceptables et leurs combinaisons.
  5. Préparation destinée à être utilisée selon l'une des revendications précédentes, caractérisée en ce que le composé métallique est choisi parmi Mn, Ag, Zn, Sn, Fe, Cu, Al, Ti, des combinaisons et des sels ou composés oxydes pharmaceutiquement acceptables de ceux-ci.
  6. Préparation destinée à être utilisée selon l'une des revendications précédentes, caractérisée en ce que le composé métallique est un composé métal/protéine, de préférence un composé argent/protéine.
  7. Préparation destinée à être utilisée selon l'une des revendications précédentes, caractérisée en ce que l'astringent est choisi parmi les tannins de catéchine, proanthocyanidines polymères, proanthocyanidines oligomères, oligomères ou polymères des catéchines, catéchine, épicatéchine, flavonoïdes, tannins hydrolysables, gallotannins, esters de l'acide gallique ou leurs dérivés, tannins, dérivés de l'acide caféique et de la phloroglucine, tannins de Labiées, acide rosmarinique ou ses dérivés, alun, argile et des combinaisons de ceux-ci.
  8. Préparation destinée à être utilisée selon l'une des revendications précédentes, caractérisée en ce que le désinfectant selon la revendication 1 est choisi parmi le digluconate de chlorhexidine, hexétidine, éthanol, propanol, alcool dichlorobenzylique, amylmétacrésol, menthol, lévomenthol, chlorure de déqualinium, iode, povidone iodée, violet de gentiane et des combinaisons de ceux-ci.
  9. Préparation destinée à être utilisée selon l'une des revendications précédentes, caractérisée en ce que l'huile essentielle est choisie parmi l'orange, camomille, achillée millefeuille, sauge, menthe poivrée et des combinaisons de celles-ci.
  10. Préparation destinée à être utilisée selon l'une des revendications précédentes, caractérisée en ce que le solvant est l'eau et/ou l'éthanol.
  11. Préparation destinée à être utilisée selon l'une des revendications précédentes, caractérisée en ce qu'elle contient un ou plusieurs additifs choisis parmi les adjuvants pharmaceutiques, adjuvants galéniques, substituts de sucre, édulcorants, acidifiants, promoteurs de solubilisation, épaississants, charges, colorants, conservateurs, anesthésiques locaux, arômes, aromatisants, provitamines, vitamines et des combinaisons de ceux-ci.
  12. Préparation destinée à être utilisée selon l'une des revendications précédentes, caractérisée en ce que la préparation est un spray destiné à être appliqué dans le pharynx.
  13. Préparation destinée à être utilisée selon l'une des revendications 1 à 12 pour le traitement d'une laryngite virale.
EP17700818.2A 2016-01-27 2017-01-18 Préparation pharmaceutique et son utilisation pour le traitement de la laryngite virale Active EP3407890B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE202016100357.1U DE202016100357U1 (de) 2016-01-27 2016-01-27 Pharmazeutische Zubereitung und deren Verwendung bei viralen, entzündlichen Erkrankungen der oberen Atemwege
PCT/EP2017/050938 WO2017129457A1 (fr) 2016-01-27 2017-01-18 Préparation pharmaceutique et son utilisation pour le traitement de maladies inflammatoires virales des voies respiratoires hautes

Publications (3)

Publication Number Publication Date
EP3407890A1 EP3407890A1 (fr) 2018-12-05
EP3407890B1 true EP3407890B1 (fr) 2023-07-19
EP3407890C0 EP3407890C0 (fr) 2023-07-19

Family

ID=55644505

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17700818.2A Active EP3407890B1 (fr) 2016-01-27 2017-01-18 Préparation pharmaceutique et son utilisation pour le traitement de la laryngite virale

Country Status (5)

Country Link
EP (1) EP3407890B1 (fr)
DE (1) DE202016100357U1 (fr)
ES (1) ES2957220T3 (fr)
PL (1) PL3407890T3 (fr)
WO (1) WO2017129457A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018325461B2 (en) * 2017-09-02 2020-06-11 Iview Therapeutics, Inc. In situ gel-forming pharmaceutical compositions and uses thereof for sinus diseases
IT202000025963A1 (it) * 2020-11-02 2022-05-02 Neilos S R L “composizione per la prevenzione e il trattamento di affezioni dell’apparato respiratorio”

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018133A1 (fr) * 1991-04-11 1992-10-29 Drore Eisen Procede de traitement par bains de bouche a base de steroides
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
ES2214135B1 (es) * 2003-02-21 2005-05-01 Laboratorios Kin S.A. Composicion para el tratamiento de la cavidad bucal y utilizaciones correspondientes.
US20100190735A1 (en) * 2006-03-28 2010-07-29 Myrex Pharmaceuticals Inc. Mouthwash and Method of Using Same for the Treatment of Mucositis or Stomatitis
ITFI20080035A1 (it) * 2008-02-26 2009-08-27 Italmed S R L Composizione odontoiatrica per la prevenzione ed il trattamento della stomatite e delle ulcerazoni della mucosa orale
EP2110116A1 (fr) * 2008-04-14 2009-10-21 Tentan AG Préparations antiseptiques aqueuses pour la zone de la bouche et de la gorge
ITMI20120019A1 (it) * 2012-01-10 2013-07-11 Restituta Castellaccio Colluttorio
BR112015022841A8 (pt) * 2013-03-15 2017-10-03 Api Genesis Llc Composições de polifenol/flavonoide e métodos de formular produtos de higiene oral

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. M. WOOD ET AL: "Laryngitis", BMJ, vol. 349, no. oct09 21, 9 October 2014 (2014-10-09), pages g5827 - g5827, XP055686402, DOI: 10.1136/bmj.g5827 *

Also Published As

Publication number Publication date
ES2957220T3 (es) 2024-01-15
EP3407890A1 (fr) 2018-12-05
DE202016100357U1 (de) 2016-03-09
WO2017129457A1 (fr) 2017-08-03
PL3407890T3 (pl) 2023-12-04
EP3407890C0 (fr) 2023-07-19

Similar Documents

Publication Publication Date Title
EP2214658B1 (fr) Préparation contenant des osmolytes destinée à être employée en cas de muqueuses sèches
DE69721766T2 (de) Neue arzneiformulierung
EP2613793B1 (fr) Spray nasal
EP3182957B1 (fr) Composition contenant du cinéol pour application nasale
EP1455803A1 (fr) Composition pharmaceutique pour une utilisation ophtalmologique et rhinologique
WO2008148572A1 (fr) Combinaisons de principes actifs anti-inflammatoires pour le traitement de maladies de la peau et des muqueuses
EP2818163B1 (fr) Composition pour l'application nasale ayant une stabilité améliorée
EP3606505B1 (fr) Composition pour application nasale
EP3407890B1 (fr) Préparation pharmaceutique et son utilisation pour le traitement de la laryngite virale
DE102005053926B3 (de) Verwendung eines antibakteriellen Mittels aus einer Mischung aus Pflanzendrogen oder Extrakten daraus
WO2010015253A1 (fr) Composition pharmaceutique pour application nasale
EP3285791B1 (fr) Composition pour le traitement de la cavité laryngopharyngée
DE202006005924U1 (de) Zusammensetzung zur Behandlung von Rhinitis
EP1239853A1 (fr) Produit fongicide contenant de la n-chlorotaurine et son utilisation
DE202020102037U1 (de) Kupferhaltige Wasserlösliche Zusammensetzung
EP3285790A1 (fr) Composition pour le traitement de la cavité laryngopharyngée
WO2008092826A2 (fr) Extraits de ciste
EP3273997B1 (fr) Compositions pour le traitement des rhinites
DE102004008375B4 (de) Verwendung von physiologisch verträglichen Ascorbatverbindungen in Kombination mit einem Sympathomimetikum als lokales Therapeutikum für Schleimhäute der Atemwege
WO2004032896A1 (fr) Preparation pharmaceutique a application nasale et son procede de production
AT508949B1 (de) Antimikrobielles, viruzides und fungizides gemisch
DE102005059420B4 (de) Verwendung einer Hypromellose enthaltende zu einer Buccaltablette gepressten Haftpaste zur Behandlung lokaler Erkrankungen der Mundschleimhaut
DE202009008263U1 (de) Zusammensetzung zur Behandlung entzündlicher Erkrankungen
DE202015104329U1 (de) Zusammensetzung für die Behandlung des Hals-/Rachenraums
EP0530455A1 (fr) Médicament nasal contenant un huminate

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180720

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200422

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: VAUBEL, NICOLA

Owner name: SOMMER, PETER

RIN1 Information on inventor provided before grant (corrected)

Inventor name: VAUBEL, NICOLA

Inventor name: SOMMER, PETER

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: VAUBEL, NICOLA

Owner name: SOMMER, PETER

RIN1 Information on inventor provided before grant (corrected)

Inventor name: VAUBEL, NICOLA

Inventor name: SOMMER, PETER

REG Reference to a national code

Ref country code: DE

Ref document number: 502017015069

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0031573000

Ref legal event code: R079

Ipc: A61P0031120000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/12 20060101ALI20230119BHEP

Ipc: A61K 31/155 20060101ALI20230119BHEP

Ipc: A61K 31/573 20060101ALI20230119BHEP

Ipc: A61K 31/58 20060101ALI20230119BHEP

Ipc: A61K 31/7024 20060101ALI20230119BHEP

Ipc: A61K 31/728 20060101ALI20230119BHEP

Ipc: A61K 33/38 20060101ALI20230119BHEP

Ipc: A61K 36/534 20060101ALI20230119BHEP

Ipc: A61K 38/38 20060101ALI20230119BHEP

Ipc: A61K 45/06 20060101ALI20230119BHEP

Ipc: A61P 31/12 20060101AFI20230119BHEP

INTG Intention to grant announced

Effective date: 20230131

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 502017015069

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

U01 Request for unitary effect filed

Effective date: 20230721

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI

Effective date: 20230727

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2957220

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20240115

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231020

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230719

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231019

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231119

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230719

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231020

U20 Renewal fee paid [unitary effect]

Year of fee payment: 8

Effective date: 20240123

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20240125

Year of fee payment: 8

Ref country code: ES

Payment date: 20240222

Year of fee payment: 8

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502017015069

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230719

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230719

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230719

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230719

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240123

Year of fee payment: 8

Ref country code: CH

Payment date: 20240202

Year of fee payment: 8

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20240115

Year of fee payment: 8

26N No opposition filed

Effective date: 20240422

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230719

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230719